n two potential blockbusters in roxadustat (anemia in chronic kidney disease) and anifrolumab (lupus) in the next 12 months. Related DB Research: Lynparza survey supports market leadership in potential >$7bn class; Buy (Parkes) Pharma: 2018 Outlook: Fundamentals solid but fewer debates than in prior ye